Brooks Labs Signs MoU for Shareholding Adjustment in BSL
Brooks Laboratories Ltd has entered into a binding Memorandum of Understanding (MoU) with Steriscience Specialties Private Limited and Brooks Steriscience Limited (BSL). This follows a prior disclosure regarding the proposed sale of a portion of its shareholding in BSL. The MoU outlines the commercial understanding for Brooks Laboratories' continuing investment in BSL post-transaction. Key terms include value protection for the retained investment, anti-dilution rights, principles for capital requirements, and interim rights. The transaction is expected to reduce Brooks Laboratories' stake in BSL from 49% to 32.67% and generate an immediate cash inflow of approximately ₹106.33 crores for growth and expansion.
Key Highlights
- Brooks Labs signs binding MoU for shareholding adjustment in BSL.
- Stake in BSL to reduce from 49% to 32.67% post-transaction.
- Expected cash inflow of ₹106.33 crores for growth initiatives.
- MoU includes value protection and anti-dilution rights.
- Agreement effective for two years, subject to definitive documents and approvals.
Price Impact
More from BROOKS